Pharmaceuticals
10 Bristol Myers Squibb business development leaders
These ten Bristol Myers Squibb business development leaders hold senior director and executive director roles in business development transactions, search and evaluation, global alliances and divestitures at Bristol Myers Squibb. A reader can learn how business development leaders work at Bristol Myers Squibb from people who have held the role.
Professionals to explore
01—10David Boyko
LinkedInExperience: Senior Director, Business Development, Transactions (Oncology Hematology & Cell Therapy) · Bristol Myers Squibb
Senior Director, Business Development, Transactions (Oncology Hematology & Cell Therapy) at Bristol Myers Squibb since October 2021. His profile describes him as a lawyer and business development director; he was earlier Director, Global Business Development at Merck Animal Health and Executive Director, Corporate Transactions at Merck.
James Yang
LinkedInExperience: Senior Director, Global Alliances | Strategy and Business Development · Bristol Myers Squibb
Senior Director, Global Alliances | Strategy and Business Development at Bristol Myers Squibb since February 2026, after Director and Associate Director roles in the same group from 2020. His profile describes overseeing collaborations with external partners, including joint governance, key collaboration initiatives and conflict resolution.
Joseph P. Simeone
LinkedInExperience: Executive Director, Search & Evaluation, Immunology, Cardiovascular & Neuroscience · Bristol Myers Squibb
Executive Director, Search & Evaluation, Immunology, Cardiovascular & Neuroscience at Bristol Myers Squibb since April 2022. He previously held business development and licensing roles at Merck from 2012 to 2022, including Executive Director, Business Development & Licensing - Oncology; his profile notes both search and evaluation and transactional experience.
Linda Brennan
LinkedInExperience: Sr. Director, Business Development, Transactions · Bristol Myers Squibb
Sr. Director, Business Development, Transactions at Bristol Myers Squibb since August 2020; her profile describes co-leading with search and evaluation and therapeutic area heads on business assessments of external opportunities. She was earlier Executive Director, Business Development & Licensing at Novartis and Executive Director, BD&L and Alliance Management Finance at Sandoz.
Matt Bunn
LinkedInExperience: Executive Director, Business Development and Licensing Transactions · Bristol Myers Squibb
Executive Director, Business Development and Licensing Transactions at Bristol Myers Squibb since June 2025, after serving as Senior Director in the same group (2020–2025). He was earlier Director and Associate Director, Business Development, Technology Transactions at BMS from 2010 to 2020, after a project manager role in oncology and pharmacodiagnostics.
Meadow Green
LinkedInExperience: Senior Director, Business Development - Search and Evaluation · Bristol Myers Squibb
Senior Director, Business Development - Search and Evaluation at Bristol Myers Squibb since January 2025, after serving as Senior Director, Early Asset and Business Development (Hematology & Oncology) from 2022 to 2025. She was earlier Head of Worldwide Access Innovation at BMS and a market access and pricing lead at ZS.
Nancy Dougherty
LinkedInExperience: Executive Director, Business Development Transactions · Bristol Myers Squibb
Executive Director, Business Development Transactions at Bristol Myers Squibb since August 2024, where her profile describes leading transactions across therapeutic areas. She was earlier Senior Director (2020–2024) and Director (2016–2020) of Business Development Transactions at BMS, after Director and Associate Director roles in Business Development & Licensing at Merck.
Priya Sriraman
LinkedInExperience: Executive Director, Global Alliances, Strategy and Business Development · Bristol Myers Squibb
Executive Director, Global Alliances, Strategy and Business Development at Bristol Myers Squibb since March 2021; her profile describes building strategic relationships with R&D collaboration partners to maximize the value of external innovation. She was earlier Senior Director, Business Development and Global Alliances at Celgene.
Sean O'Leary
LinkedInExperience: Executive Director, Divestitures and Out-Licensing Transactions · Bristol Myers Squibb
Executive Director, Divestitures and Out-Licensing Transactions at Bristol Myers Squibb since February 2026, after serving as Senior Director, Divestitures - Corporate Development (2022–2026). He was earlier Director for divestitures, M&A and equity investments in BMS corporate development, and a director in global product development and supply business development.
Sévrine Broxer
LinkedInExperience: Senior Director, Business Development Transaction · Bristol Myers Squibb
Senior Director, Business Development Transaction at Bristol Myers Squibb since March 2025, after serving as Director, Business Development Transaction, Oncology, Heme and Cell Therapy (2021–2025). Earlier BMS roles include Associate Director in business development transactions and in global manufacturing and supply business development.
Choose the right perspective
Match the person's scope to your question, since search and evaluation, licensing transactions, global alliance management and divestitures or out-licensing involve different work. Check which therapeutic area and deal type the person's role covers, since that shapes what they can speak to.
Questions to take into the conversation
- 01How do search and evaluation and transaction teams split work on a licensing deal?
- 02How does a pharmaceutical company govern a research collaboration after signing?
- 03How are divestitures and out-licensing deals run compared with in-licensing?
Reaching Bristol Myers Squibb business development leaders
How can I contact one of these Bristol Myers Squibb business development leaders?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 1 company: Bristol Myers Squibb, based on profile data retrieved on October 9, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach Bristol Myers Squibb business development leaders?
You choose the offer, starting at $5 per person. It includes Instant Expert's 20% fee, so an offer that pays the person $100 costs you $125. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
Can an AI agent ask one of these Bristol Myers Squibb business development leaders a question?
Yes. An agent with a USDC wallet on Base can ask one question without an Instant Expert account. It names the person, for example by the LinkedIn URL on this page, and pays per ask over x402 (HTTP 402). The person answers in writing or by voice note, and if nobody answers within 7 days, the payment goes back to the wallet automatically. x402 docs
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot and may describe past or present roles. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.
Request a correction or removal